drugset / Trial / NCT00462072

Centocor Microarray Study of Patients

NCT00462072

Phase 4 Completed 31 enrolled University of Rochester Centocor, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs. Specific Aim 2. To analyze the change in gene expression profiles in patients with Crohn's disease, psoriatic and rheumatoid arthritis before and after infliximab therapy.

Timeline

Start
2007-03
Primary completion
2010-06
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg
Background Methotrexate Small molecule 12.5 mg
Background Methotrexate Small molecule 20 mg